Form 4: Crinetics Officer Sells Shares After Option Exercise

Crinetics Pharmaceuticals' Chief Medical and Development Officer, Dana Pizzuti, exercised stock options and subsequently sold 5,000 shares of common stock for $41.81 per share.

Summary

• Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, Inc., reported transactions on October 1, 2025.
• Pizzuti exercised options to acquire 5,000 shares of common stock at an exercise price of $16.89 per share.
• Concurrently, Pizzuti sold 5,000 shares of common stock in the open market at a volume-weighted average price of $41.81 per share, with sales prices ranging from $41.34 to $42.16.
• The sale was executed automatically pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025.
• Following these transactions, Pizzuti directly owns 66,270 shares of Crinetics Pharmaceuticals common stock.
• Pizzuti also holds 79,042 derivative securities (stock options) with an exercise price of $16.89, expiring on October 10, 2032.
• A previous Form 4 filed on September 4, 2025, inadvertently reported 96,270 shares owned, which has been corrected to 66,270 shares.

Sentiment

Score: 6

Explanation: The Chief Medical and Development Officer exercised stock options at a lower price and sold shares at a significantly higher market price, indicating a profitable transaction for the insider. The sale was pre-planned under a 10b5-1 plan, which is a neutral to slightly positive signal as it reduces concerns about opportunistic trading. A minor correction to a previous filing was noted.

Positives

• The exercise of stock options indicates that the officer sees value in the company's stock at the exercise price.
• The sale price of $41.81 per share is significantly higher than the exercise price of $16.89, indicating a profitable transaction for the officer.
• The transaction was conducted under a Rule 10b5-1 trading plan, which suggests pre-planning and reduces concerns about opportunistic insider trading.

Negatives

• An officer selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by investors, as it reduces their direct stake in the company.
• A previous filing error (Form 4 on September 4, 2025) regarding the number of beneficially owned shares required a correction, which points to minor administrative oversight.

Risks

• Administrative error in previous filings, requiring correction, though this specific instance appears minor.

Future Outlook

No explicit forward-looking statements or guidance regarding company performance were provided. The Rule 10b5-1 plan indicates pre-scheduled future transactions for the reporting person.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are common in publicly traded companies. They allow insiders to diversify holdings or manage liquidity while adhering to insider trading regulations. The exercise of options and subsequent sale is a typical event for executives whose compensation includes equity.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale by a key executive, while pre-planned, could be interpreted in various ways. The correction of a previous filing ensures accurate information for investors.
• Employees: The vesting schedule of options is tied to continued employment, which is a standard incentive mechanism for retaining key personnel.

Next Steps

• The remaining stock options will continue to vest monthly in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

Key Dates

Keywords

Crinetics Pharmaceuticals, CRNX, insider trading, Form 4, stock option, share sale, Dana Pizzuti, 10b5-1 plan, beneficial ownership